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Abstract 
Cardiomyocytes (CMs) derived from human pluripotent stem cells (hPSCs) are considered a most 
promising option for cell-based cardiac repair. Hence, various protocols have been developed for 
differentiating hPSCs into CMs. Despite remarkable improvement in the generation of hPSC-CMs, 
without purification, these protocols can only generate mixed cell populations including 
undifferentiated hPSCs or non-CMs, which may elicit adverse outcomes. Therefore, one of the 
major challenges for clinical use of hPSC-CMs is the development of efficient isolation techniques 
that allow enrichment of hPSC-CMs. In this review, we will discuss diverse strategies that have 
been developed to enrich hPSC-CMs. We will describe major characteristics of individual 
hPSC-CM purification methods including their scientific principles, advantages, limitations, and 
needed improvements. Development of a comprehensive system which can enrich hPSC-CMs will 
be ultimately useful for cell therapy for diseased hearts, human cardiac disease modeling, cardiac 
toxicity screening, and cardiac tissue engineering. 
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Introduction 
Heart failure is the leading cause of death 
worldwide [1]. Approximately 6 million people suffer 
from heart failure in the United States every year [1]. 
Despite this high incidence, existing surgical and 
pharmacological interventions for treating heart 
failure are limited because these approaches only 
delay the progression of the disease; they cannot 
directly repair the damaged hearts [2]. In the case of 
large myocardial infarction (MI), patients progress to 
heart failure and die within short time from the onset 
of symptoms [3].  
The adult human heart has minimal regenerative 
capacity, because during mammalian development, 
the proliferative capacity of cardiomyocytes (CMs) 
progressively diminishes and becomes terminally 
differentiated shortly after birth [4].Therefore, once 
CMs are damaged, they are rarely restored [5]. When 
MI occurs, the infarcted area is easily converted to 
non-contractile scar tissue due to loss of CMs and 
replacement by fibrosis [6]. Development of a 
fibroblastic scar initiates a series of events that lead to 
adverse remodeling, hypertrophy, and eventual heart 
failure [2, 3, 7]. 
While heart transplantation is considered the 
most viable option for treating advanced heart failure, 
the number of available donor hearts is always less 
than needed [6]. Therefore, more realistic therapeutic 
options have been required [2]. Accordingly, over the 
past two decades, cell-based cardiac repair has been 
intensively pursued [2, 7]. Several different cell types 
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have been tested and varied outcomes were obtained. 
Indeed, the key factor for successful cell-based cardiac 
repair is to find the optimal cell type that can restore 
normal heart function. Naturally, CMs have been 
considered the best cell type to repair a damaged 
heart [8]. In fact, many scientists hypothesized that 
implanted CMs would survive in damaged hearts and 
form junctions with host CMs and synchronously 
contract with the host myocardium [9]. In fact, animal 
studies with primary fetal or neonatal CMs 
demonstrated that transplanted CMs could survive in 
infarcted hearts [9-11]. These primary CMs reduced 
scar size, increased wall thickness, and improved 
cardiac contractile function with signs of 
electro-mechanical integration [9-11]. These studies 
strongly suggest that CMs can be a promising source 
to repair the heart. However, the short supply and 
ethical concerns disallow using primary human CMs. 
In a patient with ischemic cardiomyopathy, about 
40-50% of the CMs are lost in 40 to 60 grams of heart 
tissue [7]. Even if we seek to regenerate a fairly small 
portion of the damaged myocardium, a large number 
of human primary CMs would be required, which is 
impossible.  
Accordingly, CMs differentiated from human 
pluripotent stem cells (hPSCs) including both 
embryonic stem cells (ESCs) and induced pluripotent 
stem cells (iPSCs) have emerged as a promising 
option for candidate CMs for cell therapy [12, 13]. 
hPSCs have many advantages as a source for CMs. 
First, hPSCs have obvious cardiomyogenic potential. 
hPSC derived-CMs (hPSC-CMs) possess a clear 
cardiac phenotype, displaying spontaneous 
contraction, cardiac excitation–contraction (EC) 
coupling, and expression of cardiac transcription 
factors, cardiac ion channels, and cardiac structural 
proteins [14, 15]. Second, undifferentiated hPSCs and 
their differentiated cardiac progeny display 
significant proliferation capacity, allowing generation 
of a large number of hPSC-CMs. Lastly, many 
pre-clinical studies demonstrated that implantation of 
hPSC-CMs can repair injured hearts and improve 
cardiac function [16-19]. Histologically, implanted 
hPSC-CMs are engrafted, aligned and coupled with 
the host CMs in a synchronized manner [16-19].  
In the last two decades, various protocols for 
differentiating hPSCs into CMs have been developed 
to improve the efficiency, purity and clinical 
compatibility [20] [18]. The reported differentiation 
methods include, but are not limited to: 
differentiation via embryoid body (EB) formation [20], 
co-culture with END-2 cells [18], and monolayer 
culture [15, 21, 22]. The EB-mediated CM 
differentiation protocol is one of the most widely 
employed methods due to its simple procedure and 
low cost. However, it often becomes labor-intensive to 
produce scalable EBs for further differentiation, which 
makes it difficult for therapeutic applications. 
EB-mediated differentiation also produces 
inconsistent results, showing beating CMs from 5% to 
70% of EBs. Recently, researchers developed 
monolayer methods to complement the problems of 
EB-based methods [15, 21, 22]. In one representative 
protocol, hPSCs are cultured at a high density (up to 
80%) and treated with a high concentration of Activin 
A (100 ng/ml) for 1 day and BMP4 (10 ng/ml) for 4 
days followed by continuous culture on regular RPMI 
media with B27 [15]. This protocol induces 
spontaneous beating at approximately 12 days and 
produces approximately 40% CMs after 3 weeks. 
These hPSC-CMs can be further cultured in RPMI-B27 
medium for another 2-3 weeks without significant cell 
damage [15]. However, these protocols use media 
with proprietary formulations, which complicates 
clinical application. As shown, most monolayer-based 
methods employ B27, which is a complex mix of 21 
components. Some of the components of B27, 
including bovine serum albumin (BSA), are 
animal-derived products, and the effects of B27 
components on differentiation, maturation or subtype 
specification processes are poorly defined. In 2014, 
Burridge and his colleagues developed an advanced 
protocol that is defined, cost-effective and efficient 
[22]. By subtracting one component from B27 at a time 
and proceeding with cardiac differentiation, the 
researchers reported that BSA and L-ascorbic acid 
2-phosphate are essential components in cardiac 
differentiation. Subsequently, by replacing BSA with 
rice-derived recombinant human albumin, the 
chemically defined medium with 3 components 
(CDM3) was produced. The application of a 
GSK-inhibitor, CHIR99021, for the first 2 days 
followed by 2 days of the Wnt-inhibitor Wnt-59 to 
cells is an optimal culture condition in CDM3 
resulting in similar levels of live-cell yields and CM 
differentiation [22].  
Despite remarkable improvement in the 
generation of hPSC-CMs, obtaining pure populations 
of hPSC-CMs still remains challenging. Currently 
available methods can only generate a mixture of cells 
which include not only CMs but other cell types. This 
is one of the most critical barriers for applications of 
hPSC-CMs in regenerative therapy, drug discovery, 
and disease investigation. For Instance, cardiac 
transplantation of non-pure hPSC-CMs mixed with 
undifferentiated hPSCs or other cell types may 
produce tumors or unwanted cell types in hearts 
[23-28]. Accordingly, a pure or enriched population of 
hPSC-CMs would be required, particularly for cardiac 
cell therapy. Enriched hPSC-CMs would also be more 
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beneficial for myocardial repair due to improved 
electric and mechanical properties [29]. A pure, 
homogeneous population of hPSC-CMs would pose 
less arrhythmic risk and have enhanced contractile 
performance, and would be more useful in disease 
modeling as they better reflect native CM physiology. 
Finally, purified hPSC-CMs would better serve for 
testing drug efficacy and toxicity. Therefore, many 
researchers have tried to develop methods to purify 
CMs from cardiomyogenically differentiated hPSCs.  
There are three important topics that are not 
addressed in this review. First is the beneficial role of 
other cell types such as endothelial cells and 
fibroblasts in the integration, survival, and function of 
CMs [30-32]. We did not discuss this issue because it 
would need a separate review due to the volume of 
material. While the roles of such cells are important, 
the value of having purified hPSC-CMs is not 
diminished. Although cell mixtures or tissue 
engineered products can be used, unless purified CMs 
are employed, they would form tumors or other 
cells/tissues when implanted in vivo. Our point here 
is that even if cardiomyocytes are mixed with 
non-CMs, all cells should be clearly defined and 
purified as well. If the mixture is made in a 
non-purified or non-defined manner (for example, an 
unsophisticated top-down approach), there would be 
undefined cells that are neither CMs, ECs, nor 
fibroblasts and these unidentified cells will make 
aberrant tissues or tumors. Second, we did not deal 
with maturation of hPSC-CMs because of its broad 
scope and depth [33, 34]. Third is direct 
reprogramming or conversion of somatic cells into 
CMs. There has been another advancement in the 
generation of CMs by directly reprogramming or 
converting somatic cells into CM-like cells by 
introducing a combination of cardiac transcription 
factors (TFs) or muscle-specific microRNAs (miRNAs) 
both in vitro and in vivo [35-41]. These cells are 
referred to as induced CMs (iCMs) or cardiac-like 
myocytes (iCLMs). While this is an important 
advancement, we did not cover this topic either due to 
its size. Accordingly, this review will focus on the 
various strategies for purifying or enriching 
hPSC-CMs reported to date (Figure 1).  
Strategies for Enriching Cardiomyocytes 
Derived From hPSCs  
Manual enrichment 
Early on, researchers isolated hPSC-CMs 
manually under microscopy by mechanically 
separating out the beating areas from myogenically 
differentiating hPSC cultures [18, 20, 42]. This method 
usually generates 5-70% hPSC-CMs. Although 
generally crude, it can enrich even higher percentages 
of CMs with further culture. This manual isolation 
method has the advantage of being easy, but while it 
can be useful for small-scale research, it is very labor 
intensive and not scalable, precluding large scale 
research or clinical application. 
 
 
Figure 1. Currently available strategies for enriching cardiomyocytes derived from human pluripotent stem cells. 
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Physical enrichment 
Xu et el. reported that hPSC-CMs, due to their 
physical and structural properties, can be enriched by 
Percoll density gradient centrifugation [43]. 
Percoll was first formulated by Pertoft et al [44] and it 
was originally developed for the isolation of cells, 
organelles, or viruses by density centrifugation. The 
Percoll-based method has several advantages. The 
procedure for Percoll-based separation is very simple 
and easy, it is inexpensive, and its low viscosity 
allows more rapid sedimentation and lower 
centrifugal forces compared to a sucrose density 
gradient. Lastly, it can be prepared and kept for a long 
time in an isotonic solution to maintain osmolarity. 
Although Percoll separation has resulted in major 
improvements in hPSC-CM isolation procedures, it 
has clear limitations with regard to purity and 
scalability. Previous studies found that Percoll 
separation is only able to enrich 40 -70% of 
hPSC-CMs. It is also not compatible with large-scale 
enrichment of hPSC-CMs.  
Genetic modification based CM Isolation 
Another traditional method for purifying 
hPSC-CMs is based on the expression of a drug 
resistant gene or a fluorescent reporter gene such as 
eGFP or DsRed, which is driven by a cardiac specific 
promoter in genetically modified hPSC lines [45, 46]. 
Here, enrichment of hPSC-CMs can be achieved by 
either drug treatment to eliminate cells that do not 
express the drug resistant gene or with FACS to 
isolate fluorescent cells [47, 48].  
Briefly, enrichment of PSC-CMs by genetically 
based selection was first reported by Klug et al [49]. 
The authors generated murine ES cell lines via 
permanent gene transfection of the aminoglycoside 
phosphotransferase gene driven by the βMHC 
(MYH7) promoter. With this approach, highly 
purified murine ESC-CMs up to 99% were achieved. 
Next, several studies reported the use of various 
CM-specific promoters to enrich ESC-CMs such as 
αMhc (Myh6), Myh7, Ncx (Sodium Calcium 
exchanger) and Mlc2v (Myl2) [46, 50, 51]. In the case 
of hESCs, αMHC/EGFP hESCs were generated by 
permanent transfection of the EGFP-tagged αMHC 
promoter [52]. Similarly, an NKX2.5/eGFP hESC line 
was generated to enrich GFP positive CMs [53]. 
However, since αMHC and NKX2.5 are expressed in 
general CMs, the resulting CMs contain a mixture of 
the three subtypes of CMs, nodal-, atrial-, and 
ventricular-like CMs. To enrich only ventricular-like 
CMs, Huber et al. generated MLC2v/GFP ESCs to be 
able to isolate MLC2v/GFP positive ventricular-like 
cells by FACS [52] [54-57]. In addition, the cGATA6 
gene was used to purify nodal-like hESC-CMs [58]. 
Future studies should focus on testing new types of 
cardiac specific promoters and devising advanced 
selection procedures to improve this strategy.  
While fluorescence-based cell sorting is more 
widely used, the drug selection method may be a 
better approach to enrich high purity of hPSC-CMs 
during differentiation/culture as it does not require 
FACS. The advantage is its capability for high-purity 
cell enrichment due to specific gene-based cell sorting. 
These highly pure cells can allow more precise 
mechanistic studies and disease modeling. Despite its 
many advantages, the primary weakness of genetic 
selection is genetic manipulation, which disallows its 
use for therapeutic application. Insertion of reporter 
genes into the host genome requires viral or nonviral 
transfection/transduction methods, which can induce 
mutagenesis and tumor formation [50, 59-61].  
Surface Protein-Based Enrichment 
Practically, antibody-based cell enrichment is the 
best method for cell purification to date. When cell 
type-specific surface proteins or “marker” proteins 
are known, one can tag cells with antibodies against 
the proteins and sort the target cells by FACS or 
magnetic-activated cell sorting (MACS). The main 
advantage is its specificity and sensitivity, and its 
utility is well demonstrated in research and even in 
clinical therapy with hematopoietic cells [62]. Another 
advantage is that multiple surface markers can be 
used at the same time to isolate target cells when one 
marker is not sufficient. However, no studies have 
reported surface markers that are specific for CMs, 
even after many years. Recently, though, several 
researchers demonstrated that certain proteins can be 
useful for isolating hPSC-CMs. 
In earlier studies, KDR (FLK1 or VEGFR2) and 
PDGFR-α were used to isolate cardiac progenitor cells 
[63]. However, since these markers are also expressed 
on hematopoietic cells, endothelial cells, and smooth 
muscle cells, they could not enrich only hPSC-CMs. 
Next, two independent studies reported two surface 
proteins, SIRPA [64] and VCAM-1 [65], which it was 
claimed could specifically identify hPSC-CMs. Dubois 
et al. screened a panel of 370 known antibodies against 
CMs differentiated from hESCs and identified SIRPA 
as a specific surface protein expressed on hPSC-CMs 
[64]. FACS with anti-SIRPA antibody enabled the 
purification of CMs and cardiac precursors from 
cardiomyogenically differentiating hPSC cultures, 
producing cardiac troponin T (TNNT2, also known as 
cTNT)-positive cells, which are generally considered 
hPSC-CMs, with up to 98% purity. In addition, a 
study performed by Elliot and colleagues identified 
another cell surface marker, VCAM1 [53]. In this 
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study, the authors used NKX2.5/eGFP hESCs to 
generate hPSC-CMs, allowing the cells to be sorted by 
their NKX2.5 expression. NKX2.5 is a well-known 
cardiac transcription factor and a specific marker for 
cardiac progenitor cells [66, 67]. To identify 
CM-specific surface proteins, the authors performed 
expression profiling analyses and found that 
expression levels of both VCAM1 and SIRPA were 
significantly upregulated in NKX2.5/eGFP+ cells. 
Flow cytometry results showed that both proteins 
were expressed on the cell surface of NKX2.5/eGFP+ 
cells. Differentiation day 14 NKX2.5/eGFP+ cells 
expressed VCAM1 (71 %) or SIRPA (85%) or both 
VCAM1 and SIRPA (37%). When the FACS-sorted 
SIRPA−VCAM1−, SIRPA+ or SIRPA+VCAM1+ cells 
were further cultured, only SIRPA+ or 
SIRPA+VCAM1+ cells showed NKX2.5/eGFP+ 
contracting portion. Of note, NKX2.5/eGFP and 
SIRPA positive cells showed higher expression of 
smooth muscle cell and endothelial cell markers 
indicating that cells sorted solely based on SIRPA 
expression may not be of pure cardiac lineage. Hence, 
the authors concluded that a more purified 
population of hPSC-CMs could be isolated by sorting 
with both cell surface markers. Despite significant 
improvements, it appears that these surface markers 
are not exclusively specific for CMs as these 
antibodies also mark other cell types including 
smooth muscle cells and endothelial cells. 
Furthermore, they are also known to be expressed in 
the brain and the lung, which raises concerns whether 
these surface proteins can be used as sole markers for 
the purification of hPSC-CMs compatible for clinical 
applications.  
More recently, Protze et al. reported successful 
differentiation and enrichment of sinoatrial node-like 
pacemaker cells (SANLPCs) from differentiating 
hPSCs by using cell surface markers and an 
NKX2-5-reporter hPSC line [68]. They found that BMP 
signaling specified cardiac mesoderm toward the 
SANLPC fate and retinoic acid signaling enhanced the 
pacemaker phenotype. Furthermore, they showed 
that later inhibition of the FGF pathway, the TFGβ 
pathway, and the WNT pathway shifted cell fate into 
SANLPCs, and final cell sorting for SIRPA-positive 
and CD90-negative cells resulted in enrichment of 
SANLPCs up to ~83%. These SIRPA+CD90- cells 
showed the molecular, cellular and 
electrophysiological characteristics of SANLPCs [68]. 
While this study makes important progress in 
enriching SANLPCs by modulating signaling 
pathways, no specific surface markers for SANLPCs 
were identified and the yield was still short of what is 
usually expected for cells purified via FACS. 
MITO tracker-based enrichment 
Hattori et al. developed a highly efficient 
non-genetic method for purifying hPSC-derived CMs, 
in which they employed a red fluorescent dye, 
tetramethylrhodamine methyl ester perchlorate 
(TMRM), that can label active mitochondria. Since 
CMs contain a large number of mitochondria, CMs 
from mice and marmosets (monkey) could be strongly 
stained with TMRM [69]. They further found that 
primary CMs from several different types of animals 
and CMs derived from both mESCs and hESCs were 
successfully purified by FACS up to 99% based on the 
TMRM signals. In addition to its efficiency for CM 
enrichment, TMRM did not affect cell viability and 
disappeared completely from the cells within 24 hrs. 
Importantly, injected hPSC-CMs purified in this way 
did not form teratoma in the heart tissues. However, 
since TMRM only functions in CMs with high 
mitochondrial density, this method cannot purify 
entire populations of hPSC-CMs [64]. While originally 
TMRM was claimed to be able to isolate mature 
hPSC-CMs, mounting evidence indicates that 
hPSC-CMs are similar to immature human CMs at 
embryonic or fetal stages. Therefore, both the exact 
phenotype of the cells isolated by TMRM and its 
utility are rather questionable [33, 34]. Two 
subsequent studies demonstrated that TMRM failed 
to accurately distinguish hPSC-CMs due to the 
insufficient amounts of mitochondria [64].  
Lactate-based hPSC-CM enrichment  
Employing the unique metabolic properties of 
CMs, Tohyama et al. developed an elegant purification 
method to enrich PSC-CMs [70]. This approach is 
based on the remarkable biochemical differences in 
lactate and glucose metabolism between CMs and 
non-CMs, including undifferentiated cells. 
Mammalian cells use glucose as their main energy 
source [71]. However, CMs are capable of energy 
production from different sources such as lactate or 
fatty acids [71]. A comparative transcriptome analysis 
was performed to detect metabolism-related genes 
which have different expression patterns between 
newborn mouse CMs and undifferentiated mouse 
ESCs. These results showed that CMs expressed genes 
encoding tricarboxylic acid (TCA) cycle enzymes 
more than genes related to lipid and amino acid 
synthesis and the pentose phosphate cycle compared 
to undifferentiated ESCs. To further prove this 
observation, they compared the metabolites of these 
pathways using fluxome analysis between CMs and 
other cell types such as ESCs, hepatocytes and skeletal 
muscle cells, and found that CMs have lower levels of 
metabolites related to lipid and amino acid synthesis 
and pentose phosphate. Subsequently, authors 
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cultured newborn rat CMs and mouse ESCs in media 
with lactate, forcing the cells to use the TCA cycle 
instead of glucose, and they observed that CMs were 
the only cells to survive this condition for even 96 hrs. 
They further found that when PSC derivatives were 
cultured in lactate-supplemented and glucose- 
depleted culture medium, only CMs survived. Their 
yield of CM population was up to 99% and no tumors 
were formed when these CMs were transplanted into 
hearts. This lactate-based method has many 
advantages: its simple procedures, ease of application, 
no use of FACS for cell sorting, and relatively low 
cost. More recently, this method was applied to 
large-scale CM aggregates to ensure scalability. As a 
follow-up study, the same group recently reported a 
more refined lactate-based enrichment method which 
further depletes glutamine in addition to glucose [72]. 
The authors found that glutamine is essential for the 
survival of hPSCs since hPSCs are highly dependent 
on glycolysis for energy production rather than 
oxidative phosphorylation. The use of glutamine- and 
glucose-depleted lactate-containing media resulted in 
more highly purified hPSC-CMs with less than 
0.001% of residual PSCs [72]. One concern of this 
lactate-based enrichment method is the health of the 
purified hPSC-CMs, because physiological and 
functional characteristics of hPSC-CMs cultured in 
glucose- and glutamine-depleted media for a long 
time may have functional impairment since CMs with 
mature mitochondria were not able to survive 
without glucose and glutamine, although they were 
able to use lactate to synthesize pyruvate and 
glutamate [72]. In addition, this lactate-based strategy 
can only be applied to hPSC- CMs, but not other hPSC 
derived cells such as neuron or β-cells.  
mRNA-based method (Molecular Beacon) 
Our group also recently reported a new method 
to isolate hPSC-CMs by directly labelling cardiac 
specific mRNAs using nano-sized probes called 
molecular beacons (MBs) [29, 73, 74]. Designed to 
detect intracellular mRNA targets, MBs are 
dual-labeled antisense oligonucleotide (ODN) 
nano-scale probes with a DNA or RNA backbone, a 
Cy3 fluorophore at the 5’ end, and a Black Hole 
quencher 2 (BHQ2) at the 3’ end [75, 76]. They form a 
stem-loop (hairpin) structure in the absence of a 
complementary target, quenching the fluorescence of 
the reporter. Hybridization with the target mRNA 
opens the hairpin and physically separates the 
reporter from the quencher, allowing a fluorescence 
signal to be emitted upon excitation. The MB-based 
method can be applied to the purification of any cell 
type that has known specific gene(s) [77].  
In one study [29], we designed five MBs 
targeting unique sites in TNNT2 or MYH6/7 mRNA 
in both mouse and human. To determine the most 
efficient transfection method to deliver MBs into 
living cells, various methods were tested and 
nucleofection was found to have the highest 
efficiency. Next, we tested the sensitivity and 
specificity of MBs using an immortalized mouse CM 
cell line, HL-1, and other cell types. Finally, we 
narrowed it down to one MB, MHC-MB, which 
showed >98% sensitivity and > 95% specificity. This 
MHC-MB was applied to cardiomyogenically 
differentiated mouse and human PSCs and FACS 
sorting was performed. The resultant 
MHC-MB-positive cells expressed cardiac proteins at 
~97% when measured by flow cytometry. These 
sorted cells also demonstrated spontaneous 
contraction and all the molecular and 
electrophysiological signatures of human CMs. 
Importantly, when these purified CMs were injected 
into the mouse infarcted myocardium, they were well 
integrated into the myocardium without forming any 
tumors, and they improved cardiac function.  
In a subsequent study [74], we refined a method 
to enrich ventricular CMs from differentiating PSCs 
(vCMs) by targeting a transcription factor which is not 
robustly expressed in cells. Since vCMs are the main 
source for generating cardiac contractile forces and 
the most frequently damaged in the heart, there has 
been great demand to develop a method that can 
obtain a pure population of vCMs for cardiac repair. 
Despite this critical unmet need, no studies have 
demonstrated the feasibility of isolating ventricular 
CMs without permanently altering their genome. 
Accordingly, we first designed MBs targeting the 
Iroquois homeobox protein 4 (Irx4) mRNA, a vCM 
specific transcription factor [78, 79]. After testing 
sensitivity and specificity, one IRX4-MB was selected 
and applied to myogenically differentiated mPSCs. 
The FACS-sorted IRX4-MB-positive cells exhibited 
vCM-like action potentials in more than 98% of cells 
when measured by several electrophysiological 
analyses including patch clamp and Ca2+ transient 
analyses. Furthermore, these cells maintained 
spontaneous contraction and expression of 
vCM-specific proteins.  
The MB-based cell purification method is 
theoretically the most broadly applicable technology 
among the purification methods because it can isolate 
any target cells expressing any specific gene. Thus, the 
MB-based sorting technique can be applied to the 
isolation of other cell types such as neural-lineage 
cells or islet cells, which are critical elements in 
regenerative medicine but do not have specific surface 
proteins identified to date. In addition, theoretically, 
this technology may have the highest efficiency when 
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MBs are designed to have the maximum sensitivity 
and specificity for the cells of interest, but not others. 
These characteristics are particularly important for 
cell therapy. Despite these advantages, the delivery 
method of MB into the cells needs to be improved. So 
far, nucleofection is the best delivery method, but 
caused some cell damage with < 70% cell viability. 
Thus, development of a safer delivery method will 
enable wider application of MB-based cell 
enrichment. 
MicroRNA-based enrichment 
Recently, Miki and colleagues reported a novel 
method for purifying cells of interest based on 
endogenous miRNA activity [80]. Miki et al. employed 
several synthetic mRNA switches (= miRNA switch), 
which consist of synthetic mRNA sequences that 
include a recognition sequence for miRNA and an 
open reading frame that codes a desired gene, such as 
a regulatory protein that emits fluorescence or 
promotes cell death. If the miRNA recognition 
sequence binds to miRNA expressed in the desired 
cells, the expression of the regulatory protein is 
suppressed, thus distinguishing the cell type from 
others that do not contain the miRNA and express the 
protein. 
Briefly, the authors first identified 109 miRNA 
candidates differentially expressed in distinct stages 
of hPSC-CMs (differentiation day 8 and 20). Next, 
they found that 14 miRNAs were co-expressed in 
hPSC-CMs at day 8 and day 20 and generated 
synthetic mRNAs that recognize these 14 miRNA, 
called miRNA switches. Among those miRNA 
switches, miR-1-, miR-208a-, and 
miR-499a-5p-switches successfully enriched 
hPSC-CMs with purity of sorted cells up to 96% 
determined by TNNT2 intracellular flow cytometry. 
Particularly, hPSC-CMs enriched by the miR-1-switch 
showed substantially higher expression of several 
cardiac specific genes/proteins and lower expression 
of non-CM genes/proteins compared with control 
cells. Patch clamp confirmed that these purified 
hPSC-CMs possessed both ventricular-like and 
atrial-like action potentials.  
One of the major advantages of this technology 
is its wider applicability to other cell types. miRNA 
switches have the flexibility to design the open 
reading frame in the mRNA sequence such that any 
desired transgene can be incorporated into the 
miRNA switches to regulate the cell phenotype based 
on miRNA activity. The authors tested this possibility 
by incorporating BIM sequence, an apoptosis inducer, 
into the cardiac specific miR-1- and miR-208a switches 
and tested whether they could selectively induce 
apoptosis in non-CMs. They found that miR-1- and 
miR-208a-Bim-switches successfully enriched 
cTNT-positive hPSC-CMs without cell sorting. 
Enriched hPSC-CMs by 208a-Bim-switch were 
injected into the hearts of mice with acute MI and they 
engrafted, survived, expressed both cTNT and CX43, 
and formed gap junctions with the host myocardium. 
No teratoma was detected. In addition, other miRNA 
switches such as miR-126-, miR-122-5p-, and 
miR-375-switches targeting endothelial cells, 
hepatocytes, and β-cells, respectively, successfully 
enriched these cell types differentiated from hPSCs. 
However, identification of specific miRNAs expressed 
only in the specific cell type of interest and 
verification of their specificity in target cells will be 
key issues for continuing to use this miRNA-based 
cell enrichment method.  
Microfluidic systems 
Recent advances in biomedical engineering have 
contributed to developing systems that can isolate 
target cells using physicochemical properties of the 
cells. Microfluidic systems have been intensively 
applied for cell separation due to recent 
improvements in miniaturizing a cell culture system 
[81-83]. These advances made possible the design of 
automated microfluidic devices with cellular 
microenvironments and controlled fluid flows that 
save time and cost in experiments. Thus, there have 
been an increasing number of studies seeking to apply 
the microfluidic system for cell separation. Among the 
first, Singh et al. tested the possibility of using a 
microfluidic system for the separation of hPSC [84] by 
preparative detachment of hPSCs from differentiating 
cultures based on differences in the adhesion 
properties of different cell types. Distinct streams of 
buffer that generated varying levels of shear stress 
further allowed selective enrichment of hPSC colonies 
from mixed populations of adherent non-hPSCs, 
achieving up to 95% purity. Of note, this strategy 
produced hPSC survival rates almost two times 
higher than FACS, reaching 80%.  
Subsequently, for hPSC-CMs purification, Xin et 
al. developed a microfluidic system with integrated 
ridge-like flow derivations and fishnet-like 
microcolumns for the enrichment of hiPSC-CMs [85]. 
This device is composed of a 250 mm-long 
microfluidic channel, which has two integrated 
parallel microcolumns with surfaces functionalized 
with anti-human TRA-1 antibody for undifferentiated 
hiPSC trapping. Aided by the ridge-like surface 
patterns on the upper wall of the channel, 
micro-streams are generated so that the cell 
suspension of mixed undifferentiated hiPSCs and 
hiPSC-CMs are forced to cross the functionalized 
fishnet-like microcolumns, resulting in trapping of 
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undifferentiated hiPSCs due to the interaction 
between the hiPSCs and the columns, and the 
untrapped hiPSC-CMs are eventually separated. By 
modulating flow and coating with anti-human TRA-1 
antibody, they were able to enrich CMs to more than 
80% purity with 70% viability. While this study 
demonstrated that a microfluidic device could be 
used for purifying hPSC-CMs, it was not realistic 
because the authors used a mixture of only 
undifferentiated hiPSCs and hiPSC-CMs. In real 
cardiomyogenically differentiated hiPSCs, 
undifferentiated hiPSCs are rare and many 
intermediate stage cells or other cell types are present, 
so the idea that this simple device can select only 
hiPSC-CMs from a complex mixture is uncertain. 
Overall, the advantages of microfluidic system 
based cell isolation include fast speed, improved cell 
viability and low cost owing to the automated 
microfluidic devices that can control cellular 
microenvironments and fluid flows [86-88]. However, 
microfluidic-based cell purification methods have 
limitations in terms of low purity and scalability 
[89-92]. In fact, there have been only a few studies 
demonstrating the feasibility that microfluidic 
device-based cell separation could achieve higher 
than 80% purity of target cells. Furthermore, currently 
available microfluidic devices allow only separation 
of a small number of cells (< 1011). To employ 
microfluidic devices for large-scale cell production, 
we need to develop a next generation of microfluidic 
devices that can achieve a throughput greater than 
1011 sorted cells per hour with > 95% purity.  
Conclusion 
Having available a large quantity of a 
homogeneous population of cells of interest is an 
important factor in advancing biomedical research 
and clinical medicine, and is especially true for 
hPSC-CMs. While remarkable progress has been 
made in the methods for differentiating hPSCs into 
CMs, technologies to enrich hPSC-CMs, particularly 
those which are clinically applicable, have been 
emerging only over the last few years. Contamination 
with other cell types and even the heterogeneous 
nature of hPSC-CMs significantly hinder their use for 
several future applications such as cardiac drug 
toxicology screening, human cardiac disease 
modeling, and cell-based cardiac repair. For instance, 
cardiac drug-screening assays require pure 
populations of hPSC-CMs, so that the observed 
signals can be attributed to effects on human CMs. 
Studies of human cardiac diseases can also be more 
adequately interpreted with purified populations of 
patient derived hiPSC-CMs. Clinical applications with 
hPSC-CMs will need to be free of other PSC 
derivatives to minimize the risk of teratoma formation 
and other adverse outcomes.  
Table 1. Summary of representative methods for hPSC-CM purification 
Purification methods Purity (%) Yield or Viability (%) Tumorigenicity Scalability Clinical applicability Application to other 
type of cells 
Manual enrichment 5 - 70% > 70% Not reported Difficult No No 
Physical enrichment by percoll gradient 40 - 70% < 70% No tumor detected Difficult Yes No 
Genetic modification- based method  > 95% ~ 70% No tumor detected Yes No Yes 
Surface protein-based method > 95% ~ 70% No tumor detected Yes Yes Yes 
MITO tracker-based enrichment Up to 99% ~ 70% No tumor detected Yes Yes No 
Lactate-based enrichment Up to 99% > 80% No tumor detected Yes Yes No 
mRNA-based method (Molecular Beacon) Up to 97% < 70% No tumor detected Yes Yes Yes 
MicroRNA-based method Up to 96% ~ 90% No tumor detected Yes Yes Yes 
Microfluidic systems < 80% > 70% Not tested Difficult Yes Yes 
 
 
 
Figure 2. Schematic pictures of microfluidic device for enriching hiPSC-CMs. (A) The part of the device designed for trapping undifferentiated hiPSCs. 
(B) (Left) Illustration of the overall microfluidic device assembled with peristaltic pump, cell suspension reservoirs, and a serpentine channel. (Right) Magnified image 
showing a channel combining microcolumns and ridge-like flow derivation structures. Modified from Li et al. On chip purification of hiPSC-derived cardiomyocytes 
using a fishnet-like microstructure. Biofabrication. 2016 Sep 8;8(3): 035017 
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Therefore, development of reproducible, 
effective, non-mutagenic, scalable, and economical 
technologies for purifying hPSC-CMs, independent of 
hPSC lines or differentiation protocols, is a 
fundamental requirement for the success of hPSC-CM 
applications. Fortunately, new technologies based on 
the biological specificity of CMs such as 
MITO-tracker, molecular beacons, 
lactate-enriched-glucose depleted-media, and 
microRNA switches have been developed. In 
addition, technologies based on engineering 
principles have recently yielded a promising platform 
using microfluidic technology. While due to the short 
history of this field, more studies are needed to verify 
the utility of these technologies, the growing attention 
toward this research is a welcome move.  
Another important question raised recently is 
how to non-genetically purify chamber-specific 
subtypes of CMs such as ventricular-like, atrial-like 
and nodal-like hPSC-CMs. So far, only a few studies 
have addressed this potential with human PSCs. We 
also showed that a molecular beacon-based strategy 
could enrich ventricular CMs differentiated from 
PSCs [74]. Another study demonstrated generation of 
SA-node like pacemaker cells by using a stepwise 
treatment of various morphogens and small 
molecules followed by cell sorting with several 
sub-specific surface markers. However, the yield of 
both studies was relatively low (<85%). Given the 
growing clinical importance of chamber-specific CMs, 
the strategies for purifying specific subtypes of CM 
that are independent of hPSC lines or differentiation 
protocols should be continuously developed. A 
recently reported cell surface capture-technology [93, 
94] may facilitate identification of chamber specific 
CM proteins that will be useful for target CM 
isolation.  
In summary, technological advances in the 
purification of hPSC-CMs have opened an avenue for 
realistic application of hPSC-CMs. Although initial 
success was achieved for purification of CMs from 
differentiating hPSC cultures, questions such as 
scalability, clinical compatibility, and cellular damage 
remain to be answered and isolation of human 
subtype CMs has yet to be demonstrated. While there 
are other challenges such as maturity, in vivo 
integration, and arrhythmogenecity, this 
development of purification technology represents 
major progress in the field and will provide 
unprecedented opportunities for cell-based therapy, 
disease modeling, drug discovery, and precision 
medicine. Furthermore, the availability of 
chamber-specific CMs with single cell analyses will 
facilitate more sophisticated investigation of human 
cardiac development and cardiac pathophysiology.  
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